Acute renal allograft rejection is mediated by both alloantigen-dependent and -independent factors and is characterized by a mononuclear cell infiltrate consisting mainly of T lymphocytes, monocyte/macrophages, and occasional eosinophils (1) (2) (3) . The recruitment of these leukocytes from the peripheral circulation into the transplanted organ involves a complex interplay between a series of molecules expressed on the leukocyte and endothelial surface (4 -6) . Chemokines, a large superfamily of structurally related cytokines, have been shown to selectively promote the rapid adhesion, chemotaxis, and activation of specific leukocyte effector subpopulations (6 -9) .
Chemokines are characterized by a series of shared structural elements including the conserved cysteine residues used to define the C, C-C, C-X-C, and C-X 3 -C chemokine subgroups (where X represents an intervening amino acid residue between the first two aminoterminal proximal cysteines). All of the various biological actions of chemokines appear to be directed through their interaction with a large family of seventransmembrane spanning, G-protein-coupled receptors (7) (8) (9) . The cell type-specific expression of these receptors appears to control to a significant degree the leukocyte specificity of chemokine action (7) (8) (9) .
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the C-C chemokine subfamily, is a potent chemoattractant for T cells, monocytes, natural killer cells, basophils, and eosinophils (10) . RANTES is a ligand for a number of chemokine receptors including CCR1, CCR3, CCR5, CCR9, and DARC (Duffy antigen receptor for chemokines) in humans (7) (8) (9) (10) (11) . Most tissues can produce RANTES in response to proinflammatory stimuli such as interleukin 1␤ (IL-1␤) or tumor necrosis factor ␣ (TNF-␣) (9, 11) . Platelets sequester RANTES protein in their ␣-granules and release it during acute stages of inflammation (9, (11) (12) (13) .
Chemokines such as RANTES are thought to play pivotal roles in the cellular infiltrates that underlie various disease processes. For example, RANTES is expressed in vivo in diseases characterized by a mononuclear cell infiltrate, including delayed-type hypersensitivity, necrotizing glomerulonephritis, inflammatory lung disease, and renal allograft rejection (9, 11, 14 -18) . In studies of human kidneys undergoing acute cellular rejection, RANTES protein was found localized to mononuclear infiltrating cells, renal tubular epithelial cells, and the endothelium of peritubular capillaries (17, 18) . Since acute cellular rejection is characterized by an intravascular and interstitial cellular infiltrate consisting of monocytes/macrophages, T lymphocytes, and occasional eosinophils, RANTES is potentially a key player in the pathogenesis of acute rejection (9, 11, 17, 18) .
Based on these observations, a model for the role of RANTES in renal allograft rejection was proposed (11, 17, 18) . Early in rejection, the microvascular endothelium becomes inflamed and platelets degranulate, releasing RANTES protein that binds to the endothelial surface. The inflamed renal tubules and endothelial cells produce additional chemokines, including RANTES. The accumulated surface-bound chemokines then provide directional signals to circulating leukocytes as they roll across the endothelial surface (4 -6, 11, 17, 18) . Leukocytes recognize the surface-bound protein, up-regulate integrins, firmly adhere to the endothelial surface, and undergo diapedesis and extravasation. As the leukocytes become activated, they produce additional cytokines and chemokines, thus amplifying and propagating the inflammatory response (11, 17, 18) .
We investigated the functional role of RANTES and its receptors in rat models of acute renal allograft rejection. Modification of the amino terminus of the RANTES protein can dramatically alter its properties (19 -21) . The addition of a single methionine residue changes the agonist protein into a RANTES receptor antagonist with nanomolar potency (19) . This antagonist, Met-RANTES, is bioactive in mouse and rat (A. E. Proudfoot, unpublished results), and has been shown to suppress inflammation in murine models of allergic skin and rheumatoid arthritis and to partially inhibit necrotizing glomerulonephritis (22) (23) (24) . We describe here the effect of Met-RANTES on development of the cellular infiltrate in acute kidney transplant rejection.
MATERIALS AND METHODS

Cells used
The human monocytic tumor cell line MonoMac 6 was cultured as described previously (25) . Primary human dermal microvascular endothelial cells (DMVEC) from human neonatal foreskin were obtained from Dr. K. Degitz (Dermatology, LMU, Munich, Germany). The cells were carried in MCDB 131 media (Life Technologies, Gaithersburg, Md.) supplemented with 10% fetal calf serum (Boehringer Mannheim, Mannheim, Germany), 1 ϫ 10 -6 M hydrocortisone acetate (Sigma, St. Louis, Mo.), 0.5 g/ml dibutyryladenosinemonophosphate (Sigma), 2 mM glutamine (Seromed, Berlin, Germany), 100 U/ml penicillin, 100 g/ml streptomycin (Life Technologies GMBH, Karlsruhe, Germany), EGF 10 g/ml (Collaborative Biomedical Products, Bedford, Mass.), and incubated at 37°C and 5% CO 2 . The cells were grown on flasks, petri plates (Costar, Cambridge, Mass.), or 96-well, flat-bottom plates (Nunc, Roskilde, Denmark) precoated with 0.5% gelatin (Sigma). Cells were characterized through morphological appearance and immunofluorescence flow cytometry for CD31 surface expression.
Histology reagents
Materials for histological studies were obtained from Merck (Rahway, N.J.) and for immunological measurements from Sigma. IL-1␤ and TNF-␣ were purchased from Sigma. Generation of recombinant human RANTES and the human RAN-TES-specific monoclonal antibody VL1 was described previously (26) . Met-RANTES was produced for in vivo studies as described (19, (22) (23) (24) .
Animals and renal transplantation
Inbred male rats were used in all experiments. Lewis (LEW, RT1 l ) rats served as recipients of Fisher 344 (F344 RT1 lvl ) or Brown Norway (BN RT1 n ) kidneys. The animals, purchased from Charles River GmbH (Sulzfeld, Germany), weighed 190 to 250 g (Lew and F344) and 140 to 170 g (BN) to adjust for ureter diameter. Transplantation was performed using a modification of the technique originally described by Fisher and Lee (27) . Briefly, animals were anesthetized by etherdrop anesthesia and the donor kidney was flushed with 5 ml of ice-cold 0.9% NaCl with or without 100 g Met-RANTES. The kidney and ureter were removed en bloc including the renal artery with a 5 mm aortic cuff and the renal vein with a 3 mm vena cava patch. The kidneys were stored in 0.9% NaCl at 4°C.
The donor kidney was transplanted to the abdominal aorta and inferior vena cava of the recipient animal, below the left renal artery, by end-to-side anastomoses with 8 -0 nonabsorbable monofilament nylon suture. Ureter anastomosis was performed end-to-end with 11-0 nonabsorbable monofilament nylon suture. Total ischemic time of the donor kidney varied between 30 and 40 min. Hydronephrosis was evaluated both macroscopically at time of death and by light microscopy. All animals with hydronephrosis were excluded from the experimental groups. The left kidney of the recipient was always removed at the time of transplantation. In the Fisher to Lewis transplantation, the right kidney was left in place as an internal control for the effects of Met-RANTES. In Brown Norway to Lewis transplantations, a bilateral nephrectomy was performed at the time of transplantation.
Experimental groups
Cyclosporin A (CyA) (kindly provided by Sandoz, Basel, Switzerland) was dissolved in olive oil and administered subcutaneously (s.c.) in a concentration of 2.5 mg/kg body weight per day for 12 days, starting 4 h posttransplantation. Met-RANTES was dissolved in water, adjusted to 0.9% sodium chloride, and injected once daily intravenously (i.v.) at a dose of 200 g per day in Fisher/Lewis and 50 g per day in Brown Norway/Lewis transplantation experiments.
The experimental groups were as follows: 
Serum analysis
Blood taken from the aorta at the time of death was analyzed for creatinine, urea, using an automated serum analyzer. These measurements were only relevant in the Brown Norway to Lewis transplant model (bilateral nephrectomy).
Histology
Organs (lung, liver, kidney, spleen) were removed under deep anesthesia, quickly blotted free of blood, weighed, and processed as needed for histology, immunohistochemistry, or in situ hybridization. The organs were cut into 1 mm slices and either immersion-fixed in 4% formaldehyde in phosphate-buffered saline (PBS) pH 7.35 (PBS: 99 mM NaH 2 PO 4 , 108 mM NaH 2 PO 4 , and 248 mM NaCl) for 24 h or fixed in methacarn for 8 h, and embedded in paraffin or frozen in liquid nitrogen and stored at Ϫ80°C until used for immunohistochemistry. Light microscopy was performed on 3 M sections stained by periodic acid-Schiff or Goldner-Elastica.
Immunohistochemistry
The monoclonal antibody ED1 (Serotec/Camon) was used on methacarn fixed, paraffin-embedded tissue (3 M) to demonstrate monocytes/macrophages. An alkaline phosphatase anti-alkaline phosphatase detection system was applied for visualization (Dako, Bucks, U.K.). Controls, omitting the first or second antibody for each section tested were negative.
Morphometry
The vascular injury score for preglomerular vessels with endothelial damage, thrombus, and endothelialitis were assessed as showing no injury [0], a mild [1] , moderate [2] , and severe [3] degree of injury and evaluated in whole kidney sections including cortex, outer, and inner medulla. A degree-specific vascular injury index was defined as the percentage of vessels with the respective degree of injury encountered in a whole kidney section. The total vascular injury score was calculated as the sum of all vessels, with all degrees of vascular injury, whereby the number of vessels with degree one was multiplied by one, that of degree two, by a factor of two, and that of degree three by a factor of three (28) . Tubular damage was evaluated as nonexistent [0], mild [1] , moderate [2] , and severe [3] as judged in 20 high-power fields of cortex and outer stripe of outer medulla. The total tubular damage score was calculated as described for the total vascular injury score. The extent of interstitial infiltration by mononuclear cells was judged as nonexistent [0], mild [1] , moderate [2] , or severe [3] and the total interstitial inflammation score was calculated as described for the total vascular injury score. The number of monocytes/macrophages and T cells within capillary convolutes of glomeruli was calculated as the mean of the respective numbers in all glomeruli in one kidney section.
In situ hybridization
Single-stranded RNA probes were generated by in vitro transcription of a cDNA clone of rat RANTES (Dr. H. Sprenger, Marburg, Germany). In vitro transcription was carried out using a Trans-Probe-T kit (Pharmacia) and digoxigeninlabeled uridine triphosphate (Boehringer). The subsequent hybridization, washing, and development of color reaction were performed essentially as described (28, 29) .
RNase protection assay
Total RNA was isolated from whole rat kidney as described previously (29) . RNase protection experiments were performed using a commercial RPA kit (PharMingen, probe rCK-1). This kit allowed the simultaneous measurement of mRNA species for rat: IL-1␣, IL-1-␤, TNF-␣, TNF-␤, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, and interferon ␥ (IFN-␥), and the housekeeping genes GAPDH and L32. Total RNA (20 g) was used for each determination. The protected samples were run out on a precast gel (Quickpoint Rapid Nucleic Acid Separation System, Novex). The intensity of the specific bands was quantitated using a Molecular Dynamics Storm 840 PhosphorImager, normalized to L32 gene expression, and averaged over the three animals analyzed.
In vitro binding assay
DMVEC were grown to confluence on coated 96-well, flatbottom plates. The resultant endothelial monolayer was either left untreated or treated with IL-1␤ (0.1 to 5 ng/ml) for 12 h. The cells were then washed twice with 1ϫPBS at 4°C and fixed for 15 min at 4°C with 2% paraformaldehyde, 0.2% glutaraldehyde in 1ϫPBS. The monolayer was then washed four times with cold 1ϫPBS. The RANTES binding assay was a modification of a previously described procedure (17, 18) . Horseradish peroxidase (HRP) -conjugated, anti-human-RANTES monoclonal antibody VL1 (0.5 g/ml) was preincubated at 25°C for 30 min with an excess of recombinant human RANTES (10 g/ml) in 1ϫPBS. The chemokineantibody complex (used to assay the relative chemokine binding capacity of the microvascular endothelium) was added at 50 l per well to the fixed cells and the plates were incubated at 25°C for 45 min, followed by four rounds of washing with cold 1ϫPBS. The HRP reaction was developed for 1-4 min and the optical density at 405 nm of the plate was determined using an enzyme-linked immunoassay (ELISA) plate reader. A standard curve for relative 'fold' binding of the complex was generated by determining the signal from a serial dilution of the RANTES/VL1 monoclonal antibody complex bound to activated (5 ng/ml IL-1␤) microvascular endothelium. The results are normalized such that the relative binding to unstimulated microvascular endothelial cells represents a value of one. All experiments were performed in quadruplicate and the results displayed are representative of four separate experiments.
Fluorescence-activated cell sorting (FACS) analysis
Flow cytometry analysis of DMVEC was performed essentially as described (30) . Briefly, confluent DMVEC stimulated with or without IL-1␤ (5 ng/ml for 12 h) were trypsinized, reacted with saturating concentrations of ICAM-1 monoclonal antibody (mAb) RR1/1 (kindly provided by Dr. R. Rothlein), E-selectin mAb, VCAM-1 mAb (both Serotec) or isotype control for 30 min on ice, stained with fluorescein isothiocyanate-conjugated goat anti-mouse IgG (Boehringer Mannheim), and analyzed in a FACScan (Becton Dickinson, Rutherford, N.J.). After correction for unspecific binding, data were expressed as specific mean log fluorescence intensity in channels.
In vitro model system of monocyte recruitment on microvascular endothelium under physiological flow conditions
The interaction of monocytes with DMVEC was studied in laminar flow assays performed essentially as described (31) (32) (33) . Briefly, DMVEC were grown to confluence in 35 mm petri dishes and stimulated with IL-1␤ (5 ng/ml) for 12 h or left untreated. The plates were assembled as the lower wall in a parallel wall flow chamber and mounted on the stage of an Olympus IMT-2 inverted microscope with 20ϫ and 40ϫ phase contrast objectives. Monocytes (MonoMac 6 cells) were cultured as described (25, 34) and resuspended at 10 6 cells/ml in assay buffer (HBSS) containing 10 mM HEPES pH 7.4 and 0.5% HSA. Shortly before assay, 1 mM Mg 2ϩ and 1 mM Ca 2ϩ was added. The cell suspensions were kept in a heating block at 37°C during the assay and perfused into the flow chamber at a rate of 1.5 dyn/cm 2 for 5 min. For inhibition experiments, monocytes were preincubated with Met-RANTES at different concentrations (0.01-1 g/ml) for 30 min on ice. The number of firmly adherent cells after 5 min was quantitated in multiple fields (at least five per experiment) by analysis of images recorded with a long integration JVC 3CCD video camera and a JVC SR L 900 E video recorder and expressed as cells/mm 2 . The type of adhesion analyzed was restricted to primary, i.e., direct interactions of monocytes with endothelium. As an inverse measure of firm arrest, the number of cells rolling at reduced velocity on endothelium was determined within the last 30 s of the 5 min intervals and assessed as the percentage of all interactions in the field. The number of cells spreading or transmigrating after 5 min intervals was determined in highpower fields as described (35) and expressed as percentage of cells firmly attached.
Statistical analysis
Values are given as mean Ϯ se. Statistical analysis was performed using the Mann-Whitney U-Wilcoxon rank sum test. A P value Ͻ0.05 was considered to show a significant difference between two groups.
RESULTS
Allotransplantation of Fisher 344 (F344 RT1 lvl ) kidneys into Lewis (LEW, RT1 l ) rats
The transplantation of Fisher (344) rat kidneys into Lewis rats in the absence of immunosuppression resulted in a characteristic mononuclear cell infiltrate and tissue damage by day 7 after surgery. Histological examination showed focal mononuclear cell infiltration of the intima of preglomerular arteries and tubular interstitium. The major component of this interstitial mononuclear infiltrate consisted of monocyte/macrophage cells. The effect of Met-RANTES on this process was examined by treating transplanted animals with daily i.v. injections of Met-RANTES at 200 g per animal.
The initial injection of Met-RANTES was given within 1 h after vascular anastomosis during transplantation surgery. No additional immune suppressive agent was given during the course of the experiment. Light microscopy and immunohistology showed no obvious effect of Met-RANTES treatment on the endogenous kidney (data not shown).
During organ transplant rejection, the transplanted organ generally increases in weight due to inflammation. The results summarized in Table 1 show that Met-RANTES-treated animals had a statistically significant reduction in transplanted organ weight relative to the untreated animals. The results also suggested a reduction in T cell and monocyte infiltration of glomeruli; however, this reduction could not be considered statistically significant (Mann-Whitney U-Wilcoxon rank sum test). The most profound effects of Met-RANTES treatment are summarized in Table 2 . The data demonstrate a significant reduction in the vascular injury and tubular rejection score of the Met-RANTES-treated animals relative to that seen in the untreated animals. Although the general trend regarding interstitial rejection score showed an apparent reduction in the Met-RANTES-treated animals, this could not be considered statistically significant (Mann-Whitney U-Wilcoxon rank sum test). Histological and immunohistochemical examples showing the effects of Met-RANTES on the rejection process (day 7) are displayed in Fig. 1 and Fig. 2 . Figure 1a shows the vascular damage, with mononuclear cells present within the lumen and the wall of an artery characteristic of untreated kidneys. In contrast, a corresponding section from a Met-RANTES-treated animal ( Figure 2c , taken from an untreated rat, shows pronounced interstitial rejection with significant ED1-positive cells within the interstitium. A corresponding section from a Met-RANTES-treated animal (Fig. 2d) shows a reduction in ED1-positive cells. Figure 1e is a high magnification showing the interstitial rejection characteristic of the untreated animals with infiltrating mononuclear cells within the tubules and the tubular epithelium (e.g., tubulitis). A corresponding tissue section from a Met-RANTEStreated rat (Fig. 1f ) shows a reduction of mononuclear cells in the tubules. This phenomenon is also demonstrated in Fig. 2e , a blowup of a section taken from an untreated animal. It shows ED1-positive cells within peritubular capillaries and the interstitium. Figure 2f , a section taken from a Met-RANTES-treated rat, demonstrates a reduced infiltration of ED1-positive cells within these tissue spaces.
Localization of rat RANTES mRNA by in situ hybridization
Tissue sections taken from rejecting Fisher rat kidneys were used in in situ hybridization studies to demonstrate cell-specific expression of RANTES mRNA in the rejecting kidney. The results were similar to those previously described for RANTES expression during rejection of human renal allografts (17, 18, 26) . Strong expression by infiltrating mononuclear cells and renal tubules and limited but identifiable expression by some endothelial cells were seen. Figure 3a shows endothelial expression of RANTES. Mononuclear cells attached to and beneath the endothelium are also positive for RANTES expression. Figure 3b is a corresponding 'sense'-negative control probe. Epithelial cell expression of RANTES mRNA is shown in Fig. 3c . In the lower middle section of this figure is an erythrocyte that is negative, with RANTES expressing mononuclear cells seen just to the left and below the erythrocyte.
Met-RANTES-treated animals show a reduction in the expression of proinflammatory cytokine mRNA as determined by RNase protection assays
The increased expression of proinflammatory cytokines such as IL-1␣, IL-1␤, IL-2, IL-3, IL-6, TNF-␤, TNF-␣, and IFN-␥ are characteristic of renal transplant rejection and suggest an ongoing inflammatory process (36 -39) . We examined the effect of Met-RANTES on the expression of cytokines in transplanted Fisher rat kidneys. Wholeorgan RNA samples were isolated from control kidneys, untreated transplanted kidneys, and Met-RANTES-treated transplanted kidneys. The mRNA levels of IL-1␣, IL-1␤, TNF-␤, TNF-␣, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, and IFN-␥ were determined by RNase protection assay relative to the internal standards L32 and GAPDH. The results show that 7 days after transplantation, untreated rejecting kidneys up-regulated (relative to control kidneys) mRNAs coding for IL-1␣ (2.4-fold), TNF-␤ (3.2- fold) and IFN-␥ (1.7), with the most pronounced increase seen in IL-1␤ (8.4-fold) and TNF-␣ (4.6-fold) (Fig. 4) . No mRNA expression of IL-2, IL-4, or IL-5 was detected. The corresponding Met-RANTES-treated animals showed a reduced average expression of IL-1␣ (25%), IL-1␤ (48%), TNF-␤ (34%), TNF-␣ (24%), and IFN-␥ (24%) relative to the untreated animals.
Transplantation of Brown Norway rat kidneys into Lewis rats: effect of Met-RANTES in conjunction with low-dose cyclosporin A
We sought to determine whether Met-RANTES could complement low-dose CyA treatment. For this procedure, we chose a renal transplant model that would yield a more vigorous rejection episode: the transplantation of Brown Norway kidneys into the Lewis rat. A bilateral nephrectomy was performed at the time of transplantation. The level of CyA used (2.5 mg/kg of body weight administered s.c. per day) had previously been shown not to significantly block renal rejection in this model (28; H.-J. Gröne, unpublished results). Finally, to better detect any additive action, a reduced dose of Met-RANTES (50 g per animal per day) was used, and the experiments were run for 12 days. The results summarized in Table 3 show a statistically significant reduction in vascular and tubular damage in the Met-RANTES/ low-dose CyA-treated animals as compared with the animals treated with low-dose CyA alone. In addition, a significant reduction in mononuclear cell infiltration of interstitial spaces was seen. These histological observations were confirmed by functional measurements showing a reduction in serum creatinine in the Met-RANTES/CyA-treated animals relative to the CyA controls (0.98 Ϯ 0.12 vs. 1.42 Ϯ 0.17 mg% (nϭ3)).
Histological examples are shown in Fig. 5 (a-f ) . Figure 5a shows the typical vascular damage seen in the low-dose CyA-treated animals, while a section from a corresponding Met-RANTES/low-dose CyAtreated animal in Fig. 5b shows no vascular damage. A low-dose CyA-treated animal (Fig. 5c ) displays a glomerulus with pronounced mesangiolysis and aneurysmatic dilation of capillaries, a typical glomerular manifestation of rejection in this model. By contrast, a corresponding Met-RANTES-treated animal (Fig. 5d) demonstrates reduction of this phenomenon and reduced interstitial mononuclear cell infiltration. Figure 5e is a high magnification showing the characteristic interstitial rejection seen in the low-dose CyA-treated animals. Figure 5f shows a marked reduction in the number of mononuclear cells within the interstitial spaces and a pronounced improvement of tubular morphology in a Met-RAN-TES-treated animal. 
Direct RANTES binding and adhesion molecule expression on activated microvascular endothelium
Since a reduction of monocyte infiltration into vascular luminal spaces represented a prominent feature of Met-RANTES treatment in both transplantation models (Fig. 1a, b, Fig. 2a, b, and Fig. 5a, b) , we set out to study potential mechanisms for this effect. It has been suggested that RANTES protein, released by activated platelets or secreted by locally inflamed tissue, accumulates on the surface of inflamed endothelium where it may support monocyte recruitment (11, 17, 18) . We examined the capacity of human microvascular endothelium (DMVEC) to sequester RANTES protein using a modification of an assay previously used to detect endothelial surface binding of RANTES in tissue sections (17, 18 ). An mAb specific for RANTES was incubated with an excess of recombinant RANTES protein and the resulting complex was added to fixed microvascular endothelium that had been-treated for 12 h prior to fixation with various concentrations of IL-1␤. Using an ELISA-like format, the capacity of DMVEC to bind the antigen-mAb complex as opposed to mAb alone was determined. Whereas the microvascular endothelium could bind RANTES protein without prestimulation, the binding was significantly increased after prestimulation with IL-1␤ (Fig. 6) .
To further characterize microvascular endothelial activation, the surface expression of molecules involved in monocyte adhesion (i.e., E-selectin and the Ig superfamily members ICAM-1 and VCAM-1) was studied (30) . Analysis revealed that resting DMVEC expressed constitutive surface levels of ICAM-1, but little VCAM-1 or E-selectin was detected ( Table 4) . Activation of DMVEC with IL-1␤ for 12 h resulted in an up-regulation of ICAM-1 expression and a marked induction of VCAM-1 and E-selectin surface expression (Table 4) .
Met-RANTES blocks the firm adhesion of monocytes to inflamed microvascular endothelium but does not affect subsequent events in diapedesis
To gain insight into potential mechanisms of action of Met-RANTES, we studied whether a blockade of RANTES receptors could inhibit the firm arrest and diapedesis of monocytes on microvascular endothelium. To this end, we used human monocytic MonoMac 6 cells that show the adhesive characteristics and integrin repertoire of mature monocytes and express several chemokine receptors, including CCR1 (40) (data not shown). DMVEC were grown to confluence on petri dishes and were either left unstimulated or activated with IL-1␤ (5 ng/ml) for 12 h. The microvascular endothelium was then tested in a parallel wall flow chamber where the MonoMac 6 cells were perfused through the chamber at a shear rate of 1.5 dyn/cm 2 for 5 min. Under such physiological flow conditions, MonoMac 6 cells undergo short periods of rolling, and the attachment of a proportion of cells can be readily converted into shear-resistant arrest. After 5 min of accumulation, the number of MonoMac 6 cells that had undergone firm adhesion to the endothelium was determined (Fig. 7a) .
Few monocytic cells firmly adhered to unstimulated microvascular endothelium and the preexposure of the endothelial cells to RANTES protein showed no significant effect. Prestimulation of the microvascular endothelium with IL-1␤ resulted in an increase in shear-resistant adhesion of monocytes. Inhibition with mAb (data not shown) confirmed previous findings that this process is mediated by monocyte ␣4 and ␤2 integrins that interact with ICAM-1 and VCAM-1 expressed on activated endothelium, respectively (32, 35) . Consistent with the immobilization of RANTES in direct binding assays, preexposure of IL-1␤-activated microvascular endothelium to RANTES protein markedly enhanced the firm arrest and accumulation of monocytes within 5 min (Fig. 7a) . Notably, preincubation of monocytes with Met-RANTES at various concentrations (0.01-1 g/ml) completely blocked RANTES-mediated shear resistant adhesion of monocytes on IL-1␤-activated DMVEC (Fig. 7a and data not shown) . In parallel, the fraction of monocytes rolling on the activated microvascular endothelium, which can be used as an inverse measure of firm arrest, was reduced after preexposure to RANTES but was restored by Met-RANTES (data not shown), indicating that the number of initial interactions with the activated endothelium was unaffected. After firm arrest, a fraction of monocytes underwent shape change or spreading, and some ultimately migrated in between or under the endothelial cells. However, RANTES or Met-RANTES did not alter spreading or transmigration (Fig. 7b) , inferring the involvement of other signals. Thus, these results indicate that Met-RANTES may reduce monocyte recruitment during renal transplant rejection by blocking monocyte arrest to inflamed microvascular endothelium. However, Met-RANTES does not appear to effect the subsequent events involved in monocyte diapedesis.
DISCUSSION
The endothelium plays a critical role in the process of renal transplant rejection. Acute renal rejection can be thought of as immune-mediated inflammation. In this context, the endothelium of the grafted organ is of central importance in the local recruitment and activation of immune effector cells. Injury to the endothelium, for example, by infiltrating leukocytes, even when it is not lethal, can have serious consequences for survival of the graft. Even moderate damage can lead to loss of the normal Figure 6 . The ability of RANTES protein to bind directly to microvascular endothelium after 12 h stimulation with increasing concentrations of IL-1␤ (0.1 to 5 ng/ml) was determined. DMVEC were grown on 96-well plates and direct RANTES binding was measured using a modified ELISA procedure (17, 18) . a DMVEC were activated with IL-1␤ (5 ng/ml) or left untreated (control) for 12 h and reacted with ICAM-1, VCAM-1, E-selectin, or isotype control mAbs. The surface protein expression was analyzed by FACS in 3 independent experiments and given as specific mean fluorescence intensity (sMFI) after correction for unspecific binding in channels.
endothelial function required for adequate perfusion of the graft and enhanced production of proinflammatory cytokines that can amplify and propagate subsequent inflammatory events (41) (42) (43) .
Chemokines are thought to play pivotal roles in leukocyte recruitment and, thus, the mononuclear cell infiltrate characteristic of allograft rejection (9, 17, 18, 44 -46) . The chemokine RANTES, a chemoattractant for T cells and monocytes, is highly expressed by human and rat kidneys undergoing transplant rejection (17, 18, 44, 45) . In a study of human renal allograft rejection, RANTES protein was identified in 17/20 biopsies from kidneys undergoing acute cellular rejection (17) . RANTES mRNA was found expressed by infiltrating mononuclear cells and renal tubular epithelial cells, but expression of RANTES mRNA by endothelial cells was almost undetectable (17, 18) . In contrast, RANTES protein prominently localized to the endothelium of peritubular capillaries. This suggested that much of the RANTES protein found on the endothelium was not produced by the inflamed endothelium, but rather had been deposited there presumably through platelet degranulation (17, 18) . Thus situated, the chemokine would be ideally positioned to enhance the recruitment of monocytes and T cells into the graft.
The kinetics of RANTES mRNA expression during renal allograft rejection in the Fisher into Lewis transplant model has been described (44, 45) . We found a similar pattern of expression where upregulation of RANTES mRNA in whole kidney was seen by day 4 after transplantation (data not shown). The tissues expressing RANTES mRNA on day 7 included the epithelium, infiltrating mononuclear cells, and some endothelial cells (Fig. 3) .
A blockade of RANTES receptors using the RAN-TES analog Met-RANTES was used to study the functional role of RANTES and its receptors in the early inflammatory events associated with rejection. In the Fisher kidney into Lewis rat transplantation model, treatment with Met-RANTES led to a significant reduction in damage to the preglomerular vessels and tubules of the transplanted kidney and reduced mononuclear cell infiltration of the vascular lumen (endotheliitis). Morphologically, the untreated kidneys showed tubules with collapsed lumina and flattened epithelia with microvesicular cytoplasm whereas the Met-RANTES-treated kidneys showed excellent preservation of normal epithelial differentiation.
The expression of specific cytokines can be an indication of ongoing inflammation (36 -38, 46) . Kidneys taken from untreated animals (Fisher into Lewis) showed up-regulation of mRNAs coding for IL-1␣, IL-1␤, TNF-␣, TNF-␤, and IFN␥, with IL-1␤ and TNF-␣ showing the most pronounced increase (Fig. 4) . This is interesting given that IL-1␤ and TNF-␣ are capable of inducing the expression of a functional program related to thrombosis and inflammation (47, 48) . Through an autocrine process, damaged endothelium produces additional quantities of these cytokines, leading to amplification of inflammation (47) (48) (49) . Animals treated with Met-RANTES showed a reduced expression of each of the proinflammatory cytokines studied. This effect may be mediated through the suppression of monocytic infiltration and thus a reduction in monocyte-de- rived proinflammatory factors or, alternatively, Met-RANTES could act directly on the inflamed endothelium. We have recently demonstrated that functional chemokine receptor (CCR2) can be induced on endothelial cells (50) . Thus, Met-RANTES may also directly block chemokine-mediated signals to the endothelium.
Though Met-RANTES did not completely suppress transplant rejection, the arrest of vascular and tubular injury seen in the Met-RANTES-treated animals demonstrates that it can have a significant effect on the damage associated with vascular inflammation. The interaction between RANTES, leukocytes, and inflamed endothelium was analyzed in vitro. An increase in the direct binding of RANTES to microvascular endothelial cells was seen after pretreatment of the endothelium with IL-1␤, suggesting an induction of surface 'chemokine presentation' molecules on the activated/inflamed endothelial cells. This 'priming' effect makes intuitive sense as the direct binding of chemokines to 'normal' microvascular endothelium could promote immune effector cell binding and activation, leading to damage of the vascular tissue.
We then examined the expression of various adhesion molecules on microvascular endothelium known to be involved in the rolling and firm adhesion of monocytes. ICAM-1 was highly expressed, and some VCAM-1 and E selectin was also detected on resting DMVEC. Surface expression of each of these proteins increased significantly after treatment with IL-1␤ ( Table 4 ). The increased expression of these molecules has been described in rejecting human renal allografts (51, 52) . Thus, inflamed microvascular endothelium appears to increase its capacity to bind RANTES protein and up-regulate the expression of molecules required for the efficient rolling and firm adhesion of leukocytes.
The RANTES-induced activation of monocytes and the blockade of RANTES receptors with Met-RANTES in the context of microvascular endothelium were then studied. In these experiments, the accumulation of monocytic cells on microvascular endothelium under physiological flow conditions was assayed. In accordance with our findings in the direct RANTES binding assays, we found that preexposure of microvascular endothelium to RANTES could enhance the firm arrest of monocytes only after preactivation of the endothelium with IL-1␤. The preincubation of monocytes with Met-RANTES completely blocked the RANTES-mediated, shearresistant accumulation on the 'inflamed' microvascular endothelium. In contrast, the subsequent spreading or migration of the monocytes was not affected by RANTES or Met-RANTES, implicating other agents/chemokines in these later events in diapedesis. Our results expand on recent reports that the CXC chemokines Mig and IP-10, which are induced and immobilized on stimulated endothelium, can induce the firm adhesion of activated effector T cells under flow conditions via CXCR3. In this study, a blockade of CXCR3 with an antireceptor monoclonal antibody did not alter subsequent transmigration (33) . Moreover, soluble eotaxin has been shown to augment eosinophil adhesion in static assays. A blockade of its receptor, CCR3, with a specific monoclonal antibody revealed a contribution to firm eosinophil arrest on activated endothelium in shear flow, but a substantial inhibition was seen only in combination with an ␣4 monoclonal antibody (53) .
It has been proposed that chemokines bound to endothelial proteoglycans are protected from being washed away in vascular flow and may thereby more efficiently recruit leukocytes (18, 54, 55) . Met-RAN-TES may act in part by preventing the shear-resistant arrest and subsequent recruitment of mononuclear cells induced by RANTES and potentially other RANTES receptor cross-reactive chemokines immobilized on the inflamed microvascular endothelium. This may be a mode of action by which Met-RANTES reduces the vascular and tubular damage during acute renal transplant rejection.
CyA is a potent immunosuppressive agent often used in transplantation. Its immunosuppressive action is mediated, at least in part, through the modulation of cytokine gene expression (56) . The ability of Met-RANTES to enhance the effects of low-dose CyA treatment was studied in a second rat model of renal transplant rejection. Kidneys from Brown Norway rats were transplanted into Lewis rats. This protocol resulted in a more aggressive clinical course of rejection than that seen in the Fisher kidney into Lewis rat model. These experiments show that treatment with Met-RANTES and low-dose CyA results in a dramatic reduction in inflammatory events compared with treatment with CyA alone. Met-RANTES significantly reduced damage to vessels and tubules and caused a pronounced reduction in interstitial rejection (Table 3 , Fig. 5 ). These results have clinical relevance given the dose-dependent nephrotoxicity associated with cyclosporin therapy (56) . A reduction in the amount of cyclosporin A required to achieve sufficient immunosuppression would be of considerable benefit to the renal transplant.
Even though the clinical outcome of the renal transplant studies and the results of the in vitro experiments are clear, additional, so far undefined modes of action of Met-RANTES may also play a role in vivo. Although Met-RANTES is less potent at antagonizing CCR3-mediated effects, it is still more effective at preventing eosinophil recruitment in vivo in an allergic skin model than neutralizing the CCR3-specific ligand eotaxin (22, 57) . The efficiency of Met-RANTES in limiting the inflammation seen in our rat allograft models may be due to its ability to bind to multiple receptors and thereby block action of additional chemokines. Met-RANTES is a potent antagonist of human CCR1 (ligands: MIP-1␣, RAN-TES, MCP-3, HCC-1, MPIF-1, MIP-5, LKN-1, MIP-1␦) and retains its ability to bind to CCR5 (ligands: MIP-1␣, RANTES, MIP-1␤, MCP-2, HCC-1) (7, 8, 19, 21) . Both of these receptors are expressed by monocytes and may play a role in the early recruitment seen in allograft rejection.
The clinical advantage of antiinflammatory agents such as Met-RANTES may lie in their acute mode of action. As demonstrated here, Met-RANTES appears to slow the mononuclear cell recruitment and vascular damage seen early in rejection. Limiting damage at these early stages may lower the inclination toward development of the subsequent inflammatory events involved in the process of transplant rejection (41-43, 58, 59) . These results strongly suggest that therapies directed toward blocking of chemokines and chemokine receptors may have a positive effect on solid allograft survival.
